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Cas-Br-E and Graffi are two myeloid leukemia-inducing murine viruses. Cas-Br-E induces, in NIH-Swiss mice, mostly non-T,
non-B leukemia composed of very immature cells with no specific characteristics (Bergeron et al. (1993). Leukemia 7,
954–962). The Graffi murine leukemia virus causes exclusively myeloid leukemia, but the tumor cells are clearly of
granulocytic nature (Ru et al. (1993). J. Virol. 67, 4722). We were interested to understand the role of the long terminal repeat
(LTR) U3 region in the myeloid specificity of these two retroviruses. We used DNase I footprinting and gel mobility shift assays
to identify a number of protein binding sites within Cas-Br-E and Graffi U3 regions. The pattern of protected regions is highly
similar for the two viruses. Some factors identified in other murine leukemia viruses, like the core binding factor, also bind
to Cas-Br-E and Graffi LTR; however, other binding sites seem specific for these two viruses. Only one difference between
them was noted, at the 59 end of the U3 region. Transcriptional activity of both LTRs was also analyzed in various cell lines
and compared with other murine leukemia viruses. The results show a slight myeloid specificity for the two LTRs, and indicate
that the Graffi enhancer is quite strong in a broad range of cell types. © 1998 Academic Press
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INTRODUCTION
Replication competent murine leukemia viruses
(MuLVs) induce various types of pathologies, including
diverse hematological neoplasm, when injected into
mice. Genetic studies, mostly involving the construction
of recombinants between molecularly cloned genomes,
have identified the long terminal repeat (LTR) as a pri-
mary determinant of leukemogenic potential, disease
specificity, and the latency period of disease induction
(DesGroseillers et al., 1983, 1984a, 1984b; Gama-Soza et
al., 1994; Golemis et al., 1989; Ishimoto et al., 1985, 1987;
Savard et al., 1987). The viral transcriptional control re-
gions are located within the U3 region of the LTR, and
studies of transcriptional tissue-specific activities have
revealed a direct correlation between the target cell type
for the disease and the cell type-specific activity: T lym-
phoma-inducing retroviruses Mo-MuLV, SL3–3, and
MCF13 show a greater transcriptional activity in T cell
lines, whereas erythroleukemia-inducing Friend MuLVs
demonstrate a strong enhancer potential in erythroid
cells (Bosze et al., 1986; Hollon and Yoshimura, 1989;
Short et al., 1987; Yoshimura et al., 1993).
Dissection of those retrovirus U3 regions using protein
binding assays has revealed a very complex array of
binding sites, some of which are conserved among type
C retroviruses (Golemis et al., 1990) and some of which
are specific to one retrovirus (Gorska-Flipot and Jolicoeur,
1990; Manley et al., 1993; Nielsen et al., 1992, 1994;
Speck et al., 1987; Thornell et al., 1988; Yoshimura and
Diem, 1995). The best studied region is the enhancer,
which is composed of one to four tandem repeat; how-
ever, cis-acting sequences have also been described
upstream (Flanagan et al., 1989) and downstream (Chen
et al., 1994; Hanekak et al., 1991; Tupper et al., 1992;
Yoshimura et al., 1993; 1995) of the enhancer. Both ubiq-
uitous and tissue-specific factors interacting with the
LTR U3 region have been identified, often with overlap-
ping or even identical binding sites. The complex assem-
bly of transcription factors on the enhancer is deter-
mined by the availability of the various factors in the
infected cell and by interactions between these factors.
In fact, MuLVs can probably use different combinations
of transcription factors in different cell types, and very
subtle differences in transcriptional activity in different
cell types may influence the disease specificity. Indeed,
mutational analyses have demonstrated the importance
of the identified cis-acting elements in tissue specificity
(Boral et al., 1989; Hollon and Yoshimura, 1989; Speck et
al., 1990a; Yoshimura et al., 1993) and in leukemogenicity
(Hanekak et al., 1991; Ishimoto et al., 1987; Morrison et
al., 1995; Speck et al., 1990a; Yuen et al., 1992). Acquisi-
tion of pathogenic potential by endogenous retroviruses
has also been correlated to acquisition of U3 sequences
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bearing new protein binding sites (Lawrenz-Smith et al.,
1994, 1995; Massey et al., 1990).
The implication of the U3 region in tissue and disease
specificity has been extensively analyzed in retroviruses
inducing T lymphoma or erythroleukemia (Golemis et al.,
1989; Yuen et al., 1992), but very little is known about
retroviruses causing myeloid leukemia. We were inter-
ested to undertake a biochemical and genetic analysis of
the U3 region of two murine retroviruses that induce
myeloid leukemia: Cas-Br-E and Graffi murine leukemia
virus.
Cas-Br-E has been shown to cause neurological dis-
eases in several strains of mice and also has a leuke-
mogenic potential; it induces a wide variety of hemato-
poietic tumors, including myeloid leukemia in NFS/N
mice. However, injection in NIH-Swiss mice induces
mainly a non-T, non-B leukemia composed of very imma-
ture cells, without any myeloid or lymphoid marker (Bry-
ant et al., 1981; Rassart et al., 1996). Genetic analyses
have shown that while the neurological primary deter-
minant is borne by the gp70 envelope protein (Jolicoeur
et al., 1991; Paquette et al., 1989, 1990), the leukemogenic
determinant is dispersed in different regions of the ge-
nome, including the LTRs (Jolicoeur et al., 1985).
We recently molecularly cloned the Graffi murine leu-
kemia virus, and the molecular clones were shown to
induce in BALB/c and NFS mice the same pathology as
the parental mixture, that is, a granulocytic leukemia,
composed of myeloblasts and neutrophils with charac-
teristic donut-like nuclei (Rassart et al., 1996; Ru et al.,
1993). Two molecular clones, named GV1.2 and GV1.4,
have been obtained and cause the same pathology but
with different latency periods. Those two molecular
clones are highly similar, except for the presence of a
perfect 60-bp duplication in the U3 region of GV1.2 clone,
which displays the shorter latency period. This correla-
tion between the latency period and the number of en-
hancer repeats strongly suggests a role for the U3 region
in the leukemogenic potential and disease specificity.
Sequence comparison shows a 91% homology be-
tween Cas-Br-E and Graffi clone 1.4 U3 regions. How-
ever, if both viruses cause a hematological disorder
involving cells of the myeloid lineage, the target cells for
transformation are clearly at different stages of differen-
tiation.
In this study, we used footprint and electrophoretic
mobility shift assay (EMSA) to identify binding sites for
cellular factors in Cas-Br-E and Graffi U3 regions. Our
results reveal a very complex binding array of factors in
both viral LTRs, with no truly myeloid-specific factor.
Cas-Br-E and Graffi share most of the binding sites in
common, with the only striking difference being at the 59
end of the LTR. Their transcriptional activities have been
analyzed by reporter gene assays in various cell types
and compared with those of other murine leukemia vi-
ruses. Results show little tissue specificity; in particular,
Graffi MuLV is strongly active is every cell type tested.
Thus, disease specificity could be achieved by very sub-
tle differences in transcriptional activity in different cell
types.
RESULTS
DNase I footprint analysis of Cas-Br-E and Graffi U3
regions reveal several protected regions
We were interested to identify factors binding not only
to the putative enhancer portion (defined by analogy with
Moloney, Friend, SL3–3, and other MuLVs) but to the
entire U3 region. Although two molecular clones of Graffi
virus have been obtained (Ru et al., 1993), we chose to
analyze only the clone GV1.4 U3 region because the
binding factors are likely to be similar in clone GV1.2 LTR,
which should have only two copies of some binding
sites.
The Cas-Br-E and GV1.4 U3 regions and smaller por-
tions of them were inserted in the pBlueScript vector (see
Materials and Methods). These various fragments then
were labeled on the upper or lower strand and used to
perform DNase protection analysis using nuclear ex-
tracts from various hematopoietic cell lines. An example
of such an analysis, using MEL nuclear extracts, is
shown in Fig. 1, and results are summarized in Fig. 2. A
very complex protection pattern was observed, with at
least eight protected regions identified (regions I–VIII).
Most of them were found protected in both upper and
lower strands; however, region VIII was found protected
only in the lower strand.
Some protected regions correspond to well known
cis-acting elements, such as the CAAT box (region VII)
and the TATA box (region VIII), which showed a very
strong protection. Region IV also contains binding sites
identified in other murine retroviruses like the core ele-
ment conserved in all type C retroviruses (Golemis et al.,
1990) or LVb, an Ets-binding site identified in Moloney
MuLV (Redondo et al., 1992). However, several protected
regions lie outside the putative enhancer and do not
correspond to any known binding sites. Thus, new cis-
acting elements are likely to be involved in Cas-Br-E and
Graffi transcriptional regulation.
The footprinting analysis was performed with nuclear
extracts from erythroid cell lines (MEL), myeloid cell lines
(M1, M-NFS-60), and a T lymphoma cell line (Ti-6), with
essentially similar results. Therefore, we were not able to
detect any myeloid-specific factor by this technique. Fur-
thermore, the same regions were found protected in
Cas-Br-E and GV1.4 LTRs (although the boundaries of
footprint are different for the two viruses), despite several
sequence differences in these protected regions. Thus
the different disease specificity displayed by those two
viruses cannot be linked to gross differences in their U3
footprinting pattern.
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Detailed analysis of the binding factors by EMSA
In an attempt to detect more subtle differences in the
binding patterns of the two LTRs, protected regions were
individually studied by EMSA analysis. Double-stranded
oligonucleotides spanning each region were synthe-
sized (Fig. 2).
Regions II and VI bind ubiquitous factors. EMSA per-
formed with oligonucleotides C2 and G2 and nuclear
extracts from various cell lines revealed one strong
specific signal, present with every extracts, as well as
faster migrating complexes (Fig. 3A). The same pattern
was observed for oligonucleotides C2 and G2, despite
a four-nucleotide deletion in GV1.4 compared with
Cas-Br-E (lanes 9–12 and 13–16). Furthermore, cross-
competition was observed between the two oligonu-
cleotides (lanes 1–3 and 5–7), suggesting that the
binding site is in the common part of the two oligonu-
cleotides. This sequence seems to bind a ubiquitous
factor that is present in every cell line tested: myeloid
(M1, M-NFS-60, and WEHI-3B), erythroid (D1B), B or T
lymphoid (A20, EL4, Ti-6), or fibroblastic (NIH-3T3); the
same complex was also observed with nonmurine cell
lines, like CHO (not shown). The faster migrating sig-
nals were not consistently observed and followed the
same competition pattern as the main complex, so
they most probably represent degradation products of
this factor.
Oligonucleotides C6 and G6 also showed a simple
binding pattern composed of a doublet (marked with
arrows), which seems specific with some extracts (MEL,
M-NFS-60) but not with others (D1B, Ti6), because they
are displaced by an excess of both nonspecific and
specific oligonucleotides (see Fig. 3B for C6; the same
pattern was observed with G6). Another, nonspecific
complex (marked NS) is observed with every extract
except for M-NFS-60 and M1 extracts (lanes 5–8). Thus
the analysis does not reveal any tissue specific factor
binding to this region.
FIG. 1. DNase I protection analysis of Cas-Br-E and Graffi clone 1.4 U3 regions. Probes were prepared by labeling an EcoRI–BamHI fragment from
plasmids pCasBRV, pCasRVR, and pCasSA for Cas-Br-E U3 regions and pGrafAA and pGrafAP for GV1.4. End-labeled fragments were incubated with
15 mg of MEL nuclear extracts, digested with DNase I, and analyzed on a sequencing gel. Protected regions (labeled I–VIII) are indicated by brackets.
Sequences are numbered from the 59 end of the LTR. M indicates A1G Maxam and Gilbert sequence; 2, no nuclear extract; 1, 15 mg of MEL nuclear
extract.
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Region I shows a completely different binding pattern
in Cas-Br-E and Graffi LTRs. Region I, located at the 59
end of U3 (nucleotides 10–34), was found protected in
Graffi and Cas-Br-E LTRs. The two viruses differ at only
two positions in this region. Interestingly, EMSA analysis
showed a very different binding pattern with oligonucle-
otides C1 and G1 (Fig. 4). Oligonucleotide G1 elicited two
complexes (A and B in Fig. 4) with every hematopoietic
cell extract: band A appeared specific, in contradiction to
band B, which is only slightly weakened by the addition
of a 100-fold excess of cold G1 oligonucleotide (lanes
3–6, 11–14, and 19–22). A third, nonspecific complex is
observed with erythroid cell extracts (lanes 3–6). None of
the complexes was affected by the addition of a 100-fold
excess of cold C1 oligonucleotide (lanes 5, 13, and 21).
EMSA performed with oligonucleotide C1 showed a very
complex binding pattern, making difficult the identifica-
tion of cell type-specific factors. None of the complexes
were affected by the addition of a 100-fold excess of cold
G1 or nonspecific oligonucleotide, demonstrating their
specificity for the Cas-Br-E sequence (lanes 9 and 17 and
data not shown). Of particular interest, a very strong
signal was observed only with WEHI-3B nuclear extracts
and was completely displaced by an excess of cold C1
but not G1 oligonucleotide (C, lanes 15–18). This com-
plex was not observed with other myeloid cell extracts,
such as M1 or M-NFS-60. Another C1-specific complex
was observed with erythroid cell extracts (arrow, lanes
1–2). These results suggest that at least one erythroid
specific factor and one factor present in the myelomono-
cytic cell line WEHI-3B are able to distinguish Cas-Br-E
from Graffi U3 regions, binding only to Cas-Br-E se-
quence. To determine which of the two base difference
between Cas-Br-E and Graffi was responsible for the
differences observed in the binding species, oligonucle-
otides differing from C1 only at the 59 or 39 position were
synthesized and used in EMSA with extracts from D1B,
WEHI-3B, or Ti-6 cells. The results (data not shown)
show that the 39 position (GTT) is important for the
binding of a Cas-Br-E-specific factor because introduc-
ing the Graffi sequence at this position led to a binding
pattern similar to that observed with the Graffi oligonu-
cleotide.
Region V binds an abundant hematopoietic specific
factor. Because Cas-Br-E and GV1.4 share the same
sequence in protected region V, only one oligonucleo-
tide, CG5, was used in EMSA. As shown in Fig. 5, a
single, strong signal was observed in EMSA performed
with every hematopoietic cell extract (the somewhat
weaker signal observed with 32Dcl.3 and WEHI-3B cell
FIG. 2. Protected sequences in Cas-Br-E and GV1.4 U3 regions and oligonucleotides used in EMSA. The sequences of Cas-Br-E and Graffi clone
GV1.4 are shown, with sequence differences indicated by an asterisk and gaps needed to maximize sequence alignments indicated by dots. The
horizontal arrow indicates the region repeated in Graffi clone GV1.2. Sequences found protected (in upper or lower strand) by footprinting are boxed
(regions I–VIII). Sequence of synthetic oligonucleotides used for EMSA are underlined: C1, C2, C4, and C6 represent Cas-Br-E sequences; G1, G2,
G4, and G6 represent the corresponding GV1.4 sequences. CG5 represents both Cas-Br-E and Graffi sequences from protected region V. Cas
indicates Cas-Br-E; GV, Graffi clone GV1.4.
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lines is due to the use of microextracts, which contain
much less material). A 100-fold excess of cold CG5, but
not nonspecific oligonucleotide, completely abolished
the signal, demonstrating the specificity of the complex
(not shown). No specific signals were observed with
nonhematopoietic cell extracts (the faint bands observed
with NIH-3T3 extracts were characterized as nonspecific
by competition assays). The hematopoietic specific com-
plex showed a slight difference in mobility when extracts
from erythroid, lymphoid, or myeloid cell types were used
(compare lanes 2 and 3 with lanes 5–7). This difference
could represent the presence of different factors in dif-
ferent hemopoietic cell types. Oligonucleotide CG5 con-
tains two potential GATA sites, and indeed the CG5
binding factors present in erythroid, myeloid, and T cell
extracts have been identified as GATA-1, GATA-2, and
GATA-3, respectively (Barat and Rassart, 1998).
Region IV binds factors of the CBF family, as well as an
erythroid-specific factor. Region IV has been extensively
studied in T lymphoma-inducing retroviruses (Mo-MuLV,
SL3–3, Akv) and also in the erythroleukemia-inducing
Friend MuLV and was shown to contain various cis-
acting elements important for the disease specificity: the
core element; factors LVb, LVc, Fva; and so on (Manley et
al.,1989, 1993; Speck et al., 1987). Cas-Br-E and GV1.4
sequences differ only at one position in this region, in the
core element (Cas-Br-E, GTGGTCAA; GV1.4, GTG-
GTCGA). However, this 1-bp difference does not affect
FIG. 3. (A) EMSA of oligonucleotides from region II. Labeled C2 (lanes 1–12) or G2 (lanes 13–16) oligonucleotides were incubated with 10 mg of
nuclear extracts from M1 (lanes 1–4), Ti-6 (lanes 5–8), EL4 (lanes 9 and 13), A20 (lanes 10 and 14), D1B (lanes 11 and 15), or NIH-3T3 (lanes 12 and
16) cell lines. Lanes 1, 5, and 9–16 indicate no competition; lanes 2 and 6, competition with 100-fold excess of cold C2 oligonucleotide; lanes 3 and
7, competition with 100-fold excess of cold G2 oligonucleotide; and lanes 4 and 8, competition with cold nonspecific (NS) oligonucleotide. (B) EMSA
of oligonucleotide C6 (region VI). Labeled C6 oligonucleotide was incubated with 10-mg nuclear extracts from MEL (lanes 2–4), M-NFS-60 (lanes 5–7),
M1 (lane 8), D1B (lanes 9–11), Ti-6 (lanes 12–14), A20 (lane 15), or NIH-3T3 (lane 16) cell lines or without extract (lane 1). Competition was performed
with a 100-fold excess of cold C6 (lanes 3, 6, 10, and 13) or nonspecific (NS) (lanes 4, 7, 11, and 14) oligonucleotide. N.E. indicates nuclear extract;
Comp., competitor.
86 BARAT AND RASSART
the array of binding factors because EMSA performed
with C4 or G4 oligonucleotides showed exactly the same
binding pattern: a similar complex was observed with
extracts from T cells (Ti-6, BW5147, EL4), B cells (A20),
and myeloid cells (M1, WEHI-3B) (Fig. 6A). A faster mi-
grating complex was consistently observed with extracts
from the very immature progenitor cell line 32Dcl3 (lane
1) and sometimes observed with other myeloid cell
lines (M1, M-NFS-60). Erythroid cell extracts (D1B, CB7)
formed a different complex (Fig. 6B, lane 1, and data not
shown).
To identify these binding factors, we used oligo-
nucleotides in which either the core element (TGTG-
GT 3 TGTAAT) or the putative Ets binding site (EBS)
(CAGGAT 3 CATTAT) was destroyed. Competition ex-
periments showed that the complex formed with lym-
phoid and myeloid cell extracts, as well as the faster
migrating complex observed with 32Dcl3 extracts, are
clearly dependent on an intact core element, but not on
an intact EBS element, because oligonucleotide MutEBS
competed as well as the wild-type C4 (Fig. 6B, lanes 9
and 14), whereas oligonucleotide Mutcore did not com-
pete at all (lanes 8 and 15). The same results were
obtained with extracts from other myeloid and lymphoid
cell lines: M1, WEHI-3B, Ti-6, BW5147, and EL4 (data not
shown). On the other hand, the erythroid-specific com-
plex is not dependent on both core and EBS elements
and thus represents a clearly different factor (lanes 1–4).
Also, those binding factors could not discriminate be-
tween GV1.4 and Cas-Br-E sequences because a cross-
competition between C4 and G4 oligonucleotides was
always observed (e.g., lanes 12 and 13).
The core-dependent binding factor was further identi-
fied by supershift assays: the complex was supershifted
by an antiserum directed against the DNA binding do-
main of core binding factor a subunit (CBFa) (Fig. 6C,
lanes 3 and 7) and blocked by anti-CBFb antibodies
(lanes 4 and 8) but unaffected by a preimmune serum
(lanes 2 and 6). The erythroid-specific complex was un-
affected by those treatments. These results show that a
member of the CBF family binds to the Cas-Br-E and
Graffi U3 regions. To gain information on the biological
significance of this binding, we tested the transactivating
potential of the core binding factor on LTR-driven tran-
scription. Plasmids containing the Cas-Br-E or Graffi reg-
ulatory region in front of the CAT reporter gene (see
below) were cotransfected with a vector expressing the
human AML1 (CBFb), either full length or lacking the
transactivation domain, in COS-7 cells. Results (Fig. 6D
and data not shown) indicate that indeed, CBFa/b is able
to transactivate Cas-Br-E and Graffi expression up to
4-fold and this transactivating potential is dependent on
the presence of the AML1 transactivating domain be-
cause a form lacking this domain is inactive.
Transcriptional activity in various cell lines. Results
obtained from EMSA analysis show the presence of a
very complex array of binding factors but failed to identify
any myeloid-specific factor binding to Cas-Br-E and
Graffi U3 regions. Therefore, we decided to analyze the
transcriptional activity of these regulatory sequences in
FIG. 4. EMSA of oligonucleotides C1 and G1 (region I). End-labeled oligonucleotide C1 (lanes 1–2, 7–10, and 15–18) or G1 (lanes 3–6, 11–14, and
19–22) were incubated with nuclear extracts from D1B (lanes 1–6), M-NFS-60 (lanes 7–14), or WEHI-3B (lanes 15–22) cells. Competitions were
performed with a 100-fold excess of cold C1 (lanes 5, 8, 13, 16, and 21), G1 (lanes 2, 4, 9, 12, 17, and 20), or nonspecific (lanes 6, 10, 14, 18, and 22)
oligonucleotide. Sequence of C1 and G1 oligonucleotides is given below, and differences between Cas-Br-E and GV1.4 are underlined
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various cell types and to compare it with that of viruses
known to be erythroid specific (Friend MuLV) or lym-
phomagenic (Mo-MuLV, RadLV).
To this end, the Cas-Br-E LTR was cloned in front of the
bacterial CAT gene. A set of various LTR–CAT construc-
tions then were made by exchanging the Cas-Br-E U3
portion with those of Friend-MLV, Graffi clones 1.2 or 1.4,
Mo-MuLV, and BL/VL3 RadLV clone V13 (Rassart et al.,
1986b). This strategy was used to ensure that only the
contribution of the U3 portion of the LTR in transcriptional
activity was studied. Transient transfection assays were
performed in various cell lines: D1B (erythroid), M1,
32Dcl3 (myeloid), BW5147 (T lymphoma), Jurkat (T lym-
phoid, human), and COS-7 (fibroblast-like, SV40 trans-
formed). Table 1 summarizes the results of at least three
experiments done in triplicate for each cell line. For each
cell line, the highest CAT activity was given the arbitrary
value of 100, and the activity of the various LTRs was
compared with this highest value.
Results show that compared with Cas-Br-E, Moloney,
Friend, and VL3V13, the GV1.2 U3 region confers a very
high transcription efficiency, almost the highest in every
cell line but the T lymphoma-derived BW5147. The high-
est activity of Mo-MuLV in this latter cell line confirms the
transcriptional specificity demonstrated for this MuLV.
Surprisingly, the Graffi clone GV1.2 was stronger than the
T lymphoid-specific VL3V13 in T cell lines. The GV1.2
transcription activity is also strong in erythroid cell lines,
being almost similar to the erythroid-specific Friend
MuLV. Comparison between the GV1.2 and GV1.4 clones
of Graffi MuLV shows a difference of ;20% in every cell
type, which can be accounted for by the 60-bp duplica-
tion present in the GV1.2 U3 region. Despite a high
activity in various cell types, the Graffi LTR shows a slight
preference for myeloid lineages compared with Moloney
or Friend LTRs (see M1 and 32Dcl3 cell lines). On the
contrary, Cas-Br-E presents a rather weak transcriptional
activity and seems to be more erythroid than myeloid
because the difference between Cas-Br-E and Graffi is
smaller in D1B than in the myeloid cell lines. Results
obtained in the Jurkat cell line were very surprising:
although Cas-Br-E and Friend were not active in this cell
type, as predicted, the Graffi was higher than the two T
cell-specific viruses, Moloney and VL3V13 MuLV.
DISCUSSION
Using the two complementary approaches of footprint-
ing and EMSA, we analyzed the protein binding sites in
the U3 region of two retroviruses that induce myeloid
leukemia. Apart from the TATA and CAAT boxes, six
regions were found protected by footprinting. Other stud-
ies involving Moloney and Friend MuLVs have analyzed
only the enhancer region, composed of the direct re-
peats (Manley et al., 1989; Speck et al., 1987). However,
four of our six protected regions are located outside this
portion (regions I, II, III, and VI). This observation sug-
gests that many cis-acting elements lie outside the so-
FIG. 5. Tissue distribution of the factor binding to CG5 oligonucleo-
tide. Labeled CG5 oligonucleotide was incubated with 10 mg of nuclear
extracts from various cell lines: CB7 (lane 2), D1B (lane 3), 32DCl3 (lane
4), M1 (lane 5), WEHI-3B (lane 6), M-NFS-60 (lane 7), Ti-6 (lane 8), and
NIH-3T3 (lane 9) or without extract (lane 1). Sequence of the upper-
strand CG5 oligonucleotide is shown.
FIG. 6. Analysis of the factors binding to the core region (protected region IV). (A) EMSA of oligonucleotide C4. Labeled oligonucleotide C4 was
incubated with extracts from 32DCl3 (lane 1), M1 (lane 2), WEHI-3B (lane 3), EL4 (lane 4), BW5147 (lane 5), or A20 (lane 6) cells. (B): Competition with
mutated oligonucleotides. Labeled oligonucleotide C4 was incubated with extracts from D1B (lanes 1–5), M-NFS-60 (lanes 6–10), or 32Dcl3 (lanes
11–16) cell lines. Competitions were performed with a 100-fold excess of oligonucleotides C4 (lanes 2, 7, and 12), G4 (lanes 13), MutCore (lanes 3,
8, and 15) Mut EBS (lanes 4, 9, and 14), or a nonspecific oligonucleotide (NS) (lanes 5, 10, and 16). Sequences of oligonucleotides C4 and G4 are
shown, and EBS and Core motif are indicated. Sequences of mutated oligonucleotides are MutCore, CCAAACAGGATATCTGTAATAAGCAG; and
MutEBS, CCAAACATTATATCTGTGGTAAGCAG. (C) Identification of the core binding factors. Probe C4 was incubated with nuclear extracts from
M-NFS-60 (lanes 1–4), 32DCl3 (lanes 5–8) or EL4 (lanes 9–12) cell lines; 2 ml of preimmune serum (lanes 2, 6, and 10) or antiserum directed against
CBFa (lanes 3, 7, and 11) or CBFb (lanes 4, 8, and 12) were added. Supershift is indicated by an arrow. (D) GV1.2 transcriptional activation by AML1
(CBFa). pGV1.2CAT (1 mg) was cotransfected with various amounts of a vector expressing the full-length AML1 cDNA (AML 451) or a truncated version
lacking the transactivation domain (AML 312) in COS-7 cells as described under Materials and Methods. The CAT activity was determined and
compared with the activity observed with the empty vector, which was given the arbitrary value of 1. Mean values and standard deviations of at least
three experiments conducted independently are given.
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called enhancer region and may play an important role in
transcriptional tissue specificity and disease specificity.
Such important regions outside the enhancer have been
described for other retroviruses, like RadLV (Gorska-
Flipot and Jolicoeur, 1990) or MCF13 (Chen et al., 1994;
Tupper et al., 1992; Yoshimura et al., 1993, 1995).
The more proximal protected region, region I, proved
to be one of the most interesting because the binding
factors seem to be very different in Cas-Br-E and Graffi.
Of particular interest is the presence of two Cas-Br-E-
specific factors: one in erythroid extracts and one in
extracts from the myelomonocytic cell line WEHI-3B. This
Cas-Br-E-specific binding species seems to be depen-
dent on one nucleotide because they bind the sequence
. . . AGGTTTAG . . . but not AGGCTTAG (Fig. 4b). The latter
is absent in other myeloid cell lines like M1 or M-NFS-60.
WEHI-3B is a constitutive IL3-producing cell line due to a
proviral insertion in the IL3 gene (Lee et al., 1982).
Whether the presence of a specific binding factor is
related to this IL3 production is unclear. It thus will be
interesting to further characterize this factor.
Two other regions, II and VI, seem to bind ubiquitous
factors. Region II binds the same factor in Cas-Br-E and
Graffi GV1.4, despite a 4-nucleotide deletion in the GV1.4
sequence. Two elements have been described in this
region, which is very well conserved in all MuLV LTRs
(Golemis et al., 1990): the LBP (LTR binding protein)
recognizes sequence TAACGCCAATT (Tsukiyama et al.,
1989), and UCR (upstream control region) contains the
two binding sites UCR-L (CGCCAT) and UCR-U (CGC-
CATTTT) (Flanagan et al., 1989). Both are present in
Cas-Br-E and GV1.4 sequences. UCR-U binds YY1, a
ubiquitously expressed zinc finger protein that is a neg-
ative regulator of Mo-MuLV expression but a positive
regulator of the intracisternal A particle (IAP) expression
(Satyamoorthy et al., 1993). The binding factor observed
in this study could be YY1. Because the influence of YY1
in transcription varies in different cell types (possibly by
interaction with cell type-specific factors), it would be
interesting to study its action on Cas-Br-E or Graffi LTR.
We identified two putative regulatory elements in the
region between the enhancer and the promoter (regions
FIG. 6—Continued
TABLE 1
Relative Transcriptional Activity of Retroviral LTRs in Various Cell Lines
Erythroid
Myeloid T Lymphoid
CosD1B M1 32Dcl3 BW5147 Jurkat
Cas-Br-E 65 43 36 19 5 43
Friend 100a 88 70 35 8 57
GV1.2 90 100a 100a 61 100a 100a
GV1.4 81 88 80 39 80 86
Moloney 43 39 55 100a 80 23
VL3V13 63 62 56 46 38 49
SV40 3 5 4 0 1 84
Note. Reporter plasmids containing U3 region of various MuLVs upstream of the CAT gene were transfected in the indicated cell lines. Results are
the mean value of at least three experiments. The standard deviation was generally not above 10%.
a The highest CAT activity in each cell line was given the arbitrary value of 100, and the activity of other LTR-CAT constructs are expressed as
percentage activity of this highest LTR.
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V and VI, Fig. 2). This region is not well conserved among
type C retroviruses (Golemis et al., 1990), which may
indicate a role in the tissue and disease specificity
shown by individual retroviruses. A regulatory element
important for transcription regulation, as well as leuke-
mogenicity, has been identified in that region in the
MCF13 LTR (Chen et al., 1994; Tupper et al., 1992; Yo-
shimura et al., 1993, 1995). This DEN element stimulates
transcription in conjunction with the enhancer (Chen et
al., 1994; Yoshimura et al., 1993), with its role being more
important when only one enhancer repeat is present.
Because Cas-Br-E and GV1.4 LTRs have only one en-
hancer repeat, this region could have a major effect on
transcription regulation. Region V (180–210), which is
perfectly conserved between Cas-Br-E and Graffi MuLVs,
showed on EMSA analysis a very strong, specific com-
plex in hematopoietic cell types. We have shown that
members of the GATA family of transcription factors
(GATA-1, GATA-2, and GATA-3) are responsible for this
complex. Moreover, those three factors are able to trans-
activate the transcription driven by Cas-Br-E, GV1.2, and
GV1.4 LTRs (Barat and Rassart, 1998).
Region VI appears to bind a single factor that is
present in every cell type tested. An E-box, similar to the
EM/F described in Friend and Moloney MuLVs (Nielsen et
al., 1994), is present in this region. At least two factors
binding the E-boxes present in Akv U3 region have been
cloned: AFL-1 and AFL-2, both members of the b-HLH
family (Nielsen et al., 1994). ALF-1 was shown to trans-
activate the LTRs of Akv, SL3–3, Moloney, and SFFV
(Nielsen et al., 1994). E47 was also shown to influence
enhancer function of recombinant MuLVs with a U3 re-
gion from a xenotropic endogenous retrovirus (Lawrenz-
Smith and Thomas, 1995); moreover, the very high leu-
kemogenicity of these recombinant viruses seems re-
lated to the acquisition of those E-boxes (Lawrenz-Smith
et al., 1994; Massey et al., 1994). Class A b-HLH factors
are mostly ubiquitously expressed (and thus may be
responsible for the complex observed with C6 or G6
oligonucleotides), and their tissue specificity is achieved
by forming heterodimers with more specific class B b-
HLH. Thus b-HLH factors, acting through E-boxes, could
possibly be important determinants for the transcrip-
tional activity and leukemogenicity of many MuLVs.
Region IV is highly conserved among MuLVs and con-
tains binding sites common to all retroviruses, such as
the core or LVc. The core has been shown to be a key
element for transcription tissue specificity (Morrisson et
al., 1995; Speck et al., 1990b; Zaiman et al., 1995), leuke-
mogenicity, and disease specificity of T lymphoma-induc-
ing retroviruses (Boral et al., 1989; Hollon and Yoshimura,
1989; Speck et al., 1990a). We have demonstrated the
binding of a core binding factor on Cas-Br-E and Graffi
core motifs and shown a transactivating potential of CBF
on Cas-Br-E LTRs. Binding sites for CBF have been
identified in regulatory regions of myeloid-specific
genes, including myeloperoxydase, neutrophil esterase,
receptors for CSFs (Nuchprayoon et al., 1994; Takahashi
et al., 1995; Zhang et al.,1994, 1996), and T cell-specific
genes (Gottschalk and Leiden, 1990; Redondo et al.,
1992; Wang and Speck, 1992; Zhang et al., 1994, 1996).
Therefore, CBF could be involved in transcription regu-
lation of myeloid-specific viruses like Graffi MuLV, as
well as T cell-specific viruses. In fact, gene disruption
has shown that CBFa/AML1 is essential for hematopoie-
sis of all lineages in the fetal liver (Okuda et al., 1996).
The 1-bp difference between Cas-Br-E and Graffi core
elements does not induce any difference in the binding
species. However, the same difference is observed be-
tween MCF13 and Akv core motifs and is thought to play
a role in T cell-specific transcription (Hollon and Yo-
shimura, 1989). This suggests that the core motif by itself
is not responsible for tissue specific expression; sur-
rounding sequences are most likely involved. Indeed,
CBF factors act in cooperation with other factors, like
Myb or ETS family members (Zaiman and Lenz, 1996;
Sun et al., 1995). In fact, CBF is able to stimulate tran-
scription only when a heterologous factor is bound to an
adjacent site (Nieves et al., 1997). An Ets binding site
(EBS) is indeed present next to the Core motif, but we
failed to demonstrate any Ets binding in our conditions.
This could be only a consequence of the gel type used in
EMSA, as demonstrated by Manley et al. (1993). Addi-
tional work is required to decipher the role of CBF in
Cas-Br-E and Graffi transcription and the identity of the
cooperating factors.
No newly myeloid-specific factor was identified in this
study. This may suggest that the transcriptional specific-
ity is not achieved by one specific factor but rather by a
delicate balance of several factors and/or by subtle dif-
ferences in factor abundance in different cell types. Al-
ternatively, we may not have analyzed the appropriate
cell lines because the target cell type for oncogenic
transformation induced by Cas-Br-E and Graffi is un-
known and may not be well represented by the various
cell lines tested here.
We analyzed transcriptional activity of Cas-Br-E, GV1.2,
and GV1.4 U3 regions in various cell types and compared
them with other viruses (Table 1). Our results show that
viral LTRs are not strictly tissue specific. The greatest
activity of Moloney in T cell types and Friend in erythroid
cells is in full accordance with previous studies (Gama-
Soza et al., 1994; LoSardo et al., 1989; Short et al., 1987).
The Graffi GV1.2 appears to have a strong transcriptional
activity in every tested cell type, therefore qualifying as a
quite versatile promoter. However, a comparison with
Moloney and Friend shows a modest myeloid specificity.
The two Graffi clones GV1.2 and GV1.4 differ in their
transcriptional activity by ;20% in most cell lines, which
is easily explained by the presence of two repeats in the
enhancer of the GV1.2 clone. This difference in transcrip-
tional activity is probably responsible for the longer la-
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tency of disease induction showed by the shortest clone,
GV1.4 (Ru et al., 1993). Also, this modest difference in
transcriptional activity confirms the importance of regu-
latory elements located outside the enhancer repeats.
Other studies suggested a variable importance of direct
repeats in various cell types: deletion of one direct re-
peat in Mo-MuLV enhancer caused a 50% reduction in
transcriptional activity in a T lymphoma cell line but not in
CTL (LoSardo et al., 1989), whereas the same deletion of
the repeat in MCF13 LTR caused a 50% reduction in
fibroblast but not in the T cell lines (Hollon and Yo-
shimura, 1989).
In contrast to Graffi, the Cas-Br-E is a quite weak
promoter, and its specificity appears more erythroid than
myeloid because the difference in transcription effi-
ciency between Cas-Br-E and Graffi U3 region is smaller
in erythroid than in myeloid cell lines. This more ery-
throid nature of Cas-Br-E compared with Graffi is sup-
ported by the high sequence homology between Cas-
Br-E and Friend MuLV LTRs (92%) and by the pathologies
induced in mice: although Graffi MuLV induces 100% of
myeloid granulocytic leukemia, the Cas-Br-E induces a
non-T, non-B leukemia composed of very immature cells
devoid of any lymphoid or myeloid surface markers. The
leukemic cells could therefore belong to a bipotential
myeloid/erythroid lineage. Furthermore, in certain condi-
tions, Cas-Br-E can induce a certain incidence of eryth-
roleukemia (Bergeron et al., 1993; Boral et al., 1989).
The relation between transcriptional tissue specificity
and disease specificity has been demonstrated for vari-
ous MuLVs. A better expression in a given cell type will
lead to a faster replication of the virus, which in turn will
lead to a greater probability of proviral integration in the
vicinity of a proto-oncogene. One other possibility is that
the strength of the enhancer or promoter is important to
activate a particular oncogene in a particular cell type,
leading to oncogenic transformation. In this regard, even
subtle differences in transcriptional activity may be suf-
ficient to achieve disease specificity. Work is in progress
to assess the exact role of the Graffi U3 region in the
induction of myeloid leukemia. Nevertheless, one must
bear in mind the great influence of the host in the dis-
ease specificity of MuLV: for example, an Mo-MuLV with
mutated core motif was shown to induce 60% erythro-
leukemia in NFS mice but almost 100% T lymphoma in
Balb/C mice (Yuen et al., 1992). Induction of a disease by
a virus is the result of many factors involving viral enve-
lope proteins and regulatory regions, cell surface recep-
tors, and the immune response of the host.
MATERIALS AND METHODS
Plasmid construction
Standard methods (Sambrook et al., 1989) were fol-
lowed in all plasmid constructions.
To facilitate the footprinting analysis, various frag-
ments of Cas-Br-E (Rassart et al., 1986a) and Graffi clone
GV1.4 (Ru et al., 1993) U3 regions were cloned in the
SmaI site of pBlueScript to generate the following plas-
mids: for U3 Cas-Br-E, pCasRR [RsaI (280) to RsaI (408)];
pCasRRV, [RsaI (280) to EcoRV (145)]; pCasRVR, [EcoRV
(145) to RsaI (408)]; and pCasSA, [Sau3AI (96) to AvaII
(191)], and for U3 Graffi, pGrafAA [AvaII (2130) to AvaII
(190)]; and pGrafAP, [AvaII (190) to KpnI (400)] (numbering
starts with the 59 end of U3).
The reporter constructs used for transient transfection
assays were made using pSV0CAT, provided by Gorman
(1982). To construct pCasCAT, an XbaI–PstI fragment
from a permuted molecular clone of Cas-Br-E (Rassart et
al., 1986a), containing two LTRs, was inserted in the
HindIII site of pSV0CAT, using HindIII linkers. One LTR
then was removed by a KpnI digestion followed by self-
ligation. The resulting plasmid contains 465 nucleotides
of the envelope gene, the entire LTR, and ;100 nucleo-
tides of the GAG gene, upstream from the bacterial CAT
gene. The others constructions were all derived from
pCasCAT, by exchanging the HindIII–KpnI (Env-U3) frag-
ment with a 0.7-kbp ClaI–KpnI from Friend helper virus
(given by Oliff et al., 1980) to generate pFriendCAT, a
0.6-kbp RsaI–KpnI fragment, from Graffi clone GV1.2 to
generate pGV1.2CAT, a 0.9-kbp RsaI–KpnI fragment, from
Graffi clone GV1.4 to generate pGV1.4CAT, a 0.85-kbp
XbaI–KpnI fragment, from RadLV BL/VL3(V13) (Rassart et
al., 1986b) to generate pVL3CAT and a 0.6-kbp ClaI–KpnI
fragment from Mo-MuLV (Muller and Muller, 1984) to
generate pMoCAT.
Plasmids pAML451 and pAML312 (given by N. Speck)
contain the cDNA of the full-length human AML1 gene or
a version lacking the transactivation domain, respec-
tively, under the control of the RSV LTR (Zaiman and
Lenz, 1996).
Cell lines and extracts
Myeloid-derived M1, M-NFS-60, WEHI-3B, and 32Dcl3;
T cell lines Ti-6, BW5147, EL4, and Jurkat; and the B-cell
line A20 were maintained in RPMI 1640 medium supple-
mented with 10% FCS, and 5% WEHI-3B conditioned
medium (Lee et al., 1982) was added as a source of IL3
for M-NFS-60 and 32Dcl3 cell lines. Erythroid cell lines
D1B, MEL and CB7 were cultured in Eagle’s MEM sup-
plemented with 10% FCS, and NIH-3T3, CHO, and COS-7
cells were cultured in DMEM plus 10% CS.
Nuclear extracts were prepared from 109 cells as de-
scribed by Wall et al. (1988). Protein concentration in the
extracts was between 5 and 15 mg/ml. Microextracts
were prepared from 106 to 107 cells as described by
Andrews and Faller (1991). Extracts were aliquoted and
stored at 280°C.
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Transient transfections and CAT assays
32Dcl3 cells were transfected with DEAE-dextran ex-
actly as described by Susow and Friedman (1993). M1
cells were transfected essentially as described by Ster-
neck et al. (1992): cells were resuspended at 2 3 106
cells/ml in TS (25 mM Tris–HCl, pH 7.4, 137 mM NaCl, 5
mM KCl, 0.6 mM Na2HPO4, 0.7 mM CaCl2, 0.5 mM
MgCl2) in conical tubes. DNA (6 mg/ml) and 0.4 mg/ml
DEAE dextran were added, and the cells were incubated
for 30 min at 37°C on a rotating wheel. Cells then were
centrifuged and resuspended in 20 ml of medium. T cell
lines were also transfected by a DEAE–dextran tech-
nique: briefly, 107 cells were washed once in TS and
resuspended in 1 ml of TS with 0.5 mg/ml DEAE–dextran
and 10 mg DNA. After a 20-min incubation at room tem-
perature, 10 ml of RPMI 1640 and 10% FCS containing
100 mM chloroquine were added, and incubation was
continued for 30 min at 37°C. The D1B cell line was
transfected with Lipofectin (GIBCO BRL): 107 cells were
washed twice with PBS and once with OptiMEM (GIBCO
BRL); they were then resuspended in 0.6 ml of OptiMEM
containing 15 mg lipofectin and 10 mg of DNA. After a
45-min incubation at 37°C, the entire mix was added to
30 ml of medium and incubated for 48 h. COS-7 cells
were transfected with DEAE–dextran, using a 10% DMSO
shock as already described.
Forty-eight hours after transfection, cells were washed
in cold PBS, and whole-cell extracts were prepared
through three freeze–thaw cycles in 0.25 M Tris–HCl, pH
7.8. Cell extracts were clarified by a 5-min centrifugation
at 10,000 g. Protein concentration was assessed by the
Bradford method (BioRad), and equal amounts of total
protein were used for the determination of CAT activity,
which was measured using 14C-acetyl-CoA and extrac-
tion with organic solvents as described previously (Sam-
brook et al., 1989). Results were expressed as the
amount of radioactivity present in the organic phase, to
which was subtracted the result obtained with mock-
transfected cells (or cells transfected with pSV0CAT). We
choose not to use a cotransfected expression vector,
such as RSV–b-gal, to monitor transfection efficiency
because we have shown that it can lead to experimental
bias, with the b-gal expression level influenced by the
presence of other plasmids (Bergeron et al., 1995). In-
stead, we performed each experiment several times, at
least in triplicate, and transfection efficiency was found
to be different from one experiment to another but very
similar for different assays in a same experiment.
Oligonucleotides
Oligonucleotides were synthesized on a Gene Assem-
bler Plus apparatus (Pharmacia) using the deoxyphos-
phoamidite method or were purchased from GSD (To-
ronto, Canada). For EMSA analyses, two complementary
oligonucleotides were synthesized for each region (their
sequences are shown in Fig. 2).
DNA–protein interaction analyses
DNase I footprinting. Probes representing various
fragments of Cas-Br-E and Graffi U3 region were labeled
with g-32P-ATP and T4 polynucleotide kinase at the EcoRI
(upper strand) or BamHI (lower strand) site of the corre-
sponding plasmid and purified on a 5% acrylamide non-
denaturing gel run in TBE. Then, 1 fmol (0.05–0.2 ng) of
labeled probe was incubated with 1 mg of poly(dI-dC)
and 10–20 mg of nuclear extract in DNase I buffer (20 mM
HEPES, pH 7.9, 8% glycerol, 40 mM KCl, 0.2 mM PMSF,
0.08 mM EDTA, 0.8 mM MgCl2, 1 mM DTT) for 20 min at
room temperature. The protein–DNA complex was then
digested with 0.1–2 mg of DNase I (Sigma) in 1 ml of 10
mM Tris–HCl, pH 7.5, for 90 s at 0°C. The reaction was
stopped by the addition of 25 ml Stop Solution (10 mM
NaCl, 0.4% SDS, 20 mM EDTA, 200 mg/ml tRNA), ex-
tracted with phenol–chloroform, and ethanol precipi-
tated. DNA was redissolved in 90% formamide loading
buffer and analyzed on 6% acrylamide sequencing gels
along with an A 1 G Maxam and Gilbert sequence. The
dried gel was autoradiographed on Kodak X-OMAT films.
EMSAs. For EMSA, 50 ng of sense oligonucleotide
was 59 end-labeled with T4 polynucleotide kinase and
g-32P-ATP and annealed with 200 ng of the complemen-
tary oligonucleotide. Then, 10 mg of nuclear extract was
added to 0.8 ng of the labeled double-stranded oligonu-
cleotide in 10 mM HEPES, pH 7.9, containing 4% glycerol,
1% Ficoll, 200 mg/ml poly(dI-dC), 25 mM KCl, 1 mM DTT,
0.5 mM EDTA, and 25 mM NaCl (10 ml total volume). After
a 20-min incubation at room temperature, 1 ml of a
solution of 20% Ficoll, 0.2% bromophenol blue, and 0.2%
xylene cyanol was added and samples were run on a 4%
acrylamide, nondenaturing gel in 0.53 TBE at 150 V for
90 min. The dried gels were autoradiographed on Kodak
X-OMAT films. For competition assays, a 100-fold excess
(80 ng) of cold double-stranded oligonucleotide was
added before the addition of the nuclear extract. For
supershift assays, nuclear extract was incubated with
1–2 ml of antibodies for 30 min at 0°C before the reac-
tion. Antisera raised against CBFa (DNA binding domain)
and CBFb were a kind gift of N. Speck.
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